The Psychedelic Executive Order: What You Need to Know

TL;DR

What happened: On April 18, 2026, President Trump signed an executive order titled Accelerating Medical Treatments for Serious Mental Illness, directing the federal government to speed up FDA review of psychedelic medicines. Six days later the FDA issued its first three priority vouchers.

How fast: The voucher cuts FDA review from ten or twelve months down to one or two. The first three went to two psilocybin programs and one MDMA-like compound. First approval is possible in late 2026 or early 2027.

When you'll have access: For most people, 2027 to 2028. Veterans and clinical-trial participants are first in line. Treatment will happen at certified clinics, not retail pharmacies.

What it doesn't change: Oregon and Colorado psilocybin programs, religious-use practices, and underground work all stay under existing federal rules.

On April 18, 2026, in the Oval Office, President Trump signed an executive order directing the federal government to accelerate access to psychedelic medicines for serious mental illness. Joe Rogan stood behind him. So did RFK Jr. and former Navy SEAL Marcus Luttrell, alongside FDA and VA leadership and veteran advocates. Six days later, the FDA followed with its first concrete actions.

I want to walk you through what the order actually does, when access becomes real for the people who need it, and what to do right now if you're looking for this work. I'll flag where the political momentum is running ahead of the clinical science, because that gap is the part that matters most for anyone who actually goes through one of these treatments.
‍

What the order does

The order activates five mechanisms. It's worth saying up front what it does not do: by itself it approves no psychedelic for medical use and creates no enforceable rights for patients or providers. It speeds up a process. It doesn't shortcut the science.

FDA priority vouchers. The order directs the FDA to issue Commissioner's National Priority Vouchers (essentially fast-pass tickets that the agency hands to specific drugs to speed their review) to psychedelic compounds that already hold Breakthrough Therapy designation (an earlier FDA label for drugs showing early promise against serious conditions). A drug with one of these vouchers goes through review in one to two months instead of the usual ten to twelve. Eli Lilly's weight-loss pill Foundayo was approved fifty days after the company filed, the fastest approval of a brand-new drug since 2002. The FDA issued the first three psychedelic vouchers on April 24. I'll get to who got them.

A Right to Try pathway for psychedelics. The order instructs the FDA and DEA to build a pathway for eligible patients to access investigational psychedelic compounds that are under FDA review and have cleared basic safety thresholds. It works through the existing Right to Try Act, the 2018 law Trump signed in his first term, rather than creating a brand-new framework. Ibogaine is named explicitly, twice. The pathway still has to be built out before patients can use it. More on that below.

$50 million in federal matching funds. HHS is directed to allocate $50 million through ARPA-H to match state investments in psychedelic research. In 2025, Texas passed legislation putting up $50 million in state funds for an ibogaine research consortium, contingent on a $50 million private match for a program of up to $100 million. No qualifying private partner has signed on. State leaders said in March 2026 they intend to fund it with state money alone, though that's still pending. The federal match looks built to encourage more states to do the same.

Early DEA rescheduling review. Rescheduling normally starts after FDA approval and takes ninety days. The order tells the Attorney General to begin rescheduling review at the completion of Phase 3 trials, which could shave up to three months off the gap between approval and prescription availability. More on what rescheduling means below.

VA, HHS, and FDA data-sharing. The VA has been running psychedelic clinical trials at multiple facilities across several states, including California, New York, Oregon, Connecticut, Nebraska, and Vermont. The order requires data-sharing agreements so that evidence from those VA trials feeds directly into FDA review. For veterans, this is the heart of the order.
‍

Who got the first vouchers

On April 24, the FDA issued three priority vouchers. The agency named the programs but not the companies. Within hours, all three confirmed themselves.

Compass Pathways, psilocybin (COMP360) for treatment-resistant depression. This was the expected one. Compass has posted positive results from two large Phase 3 trials in more than 1,000 patients, the second of which read out in February 2026. On the same day it got the voucher, the FDA also granted Compass a rolling NDA review, which lets the company submit completed pieces of its application as they're ready rather than waiting to file all at once. Compass plans to submit by the end of 2026. If approved, COMP360 would be the first classic psychedelic ever cleared by the FDA.

Usona Institute, psilocybin for major depressive disorder. Usona is a nonprofit. Its psilocybin program got Breakthrough Therapy designation back in 2019 and is now in Phase 3. It hasn't filed its application yet. There's an open question about whether a nonprofit with no commercial team is positioned to actually launch a drug, even if it's approved. It may need a partner.

Transcend Therapeutics, methylone (TSND-201) for PTSD. This was the surprise. Methylone is an MDMA-like compound, not a classic psychedelic like psilocybin or LSD, and it's the least developed of the three, only now entering Phase 3. Transcend is being acquired by the Japanese pharmaceutical company Otsuka for $1.225 billion, a deal expected to close around mid-2026.

The surprise isn't just that methylone is early. It's who didn't get the third voucher. Most of the field expected it to go to Resilient Pharmaceuticals, formerly Lykos, for its MDMA therapy for PTSD. The FDA declined to approve that program in August 2024 and asked for another Phase 3 trial. Resilient has said its data is under independent audit, and it's not clear when, or whether, it will resubmit. The voucher going to Otsuka's methylone instead of Resilient's MDMA is a real signal about where the agency's confidence sits right now.

One more action from April 24 worth flagging: the FDA cleared an early-phase study of noribogaine, a derivative of ibogaine, for alcohol use disorder. That's the first US clinical study of an ibogaine derivative. Note the distinction. This is noribogaine, not ibogaine itself. A Phase 1 study run earlier in 2026 at doses from 20 to 80 milligrams found it safe and well tolerated, without the dangerous heart-rhythm effects that have blocked ibogaine research in this country for decades.
‍

What Right to Try means for psychedelics

The Right to Try Act lets seriously ill patients request investigational drugs directly from the manufacturer, with their physician, bypassing the FDA. The drug has to have completed Phase 1 trials and still be in active development.

For psychedelics, Right to Try has been mostly theoretical. Most of these compounds are Schedule I, which means the DEA treats them as having no accepted medical use, and that drug-enforcement problem has sat on top of the access question and kept the pathway from working in practice.

The order invokes the Right to Try framework and tells the FDA and DEA to build out access from there. The mechanics, which drugs qualify, how fast a given patient can actually use it, are all still being worked out. Ibogaine is named even though it hasn't completed Phase 1 here, which suggests the administration wants a broader reading than the strict letter of the law.

Here's the honest version: don't plan your care around Right to Try being available soon. For seriously ill patients right now, the real path is clinical-trial enrollment.
‍

What rescheduling means, and why it matters to you

Every controlled substance sits in one of five federal schedules, based on accepted medical use and abuse potential. The schedule decides whether a drug can be prescribed at all, how tightly it's controlled, and what the penalties are.

Schedule I is the most restrictive: no accepted medical use, high abuse potential, can't be prescribed. Heroin, LSD, psilocybin, MDMA, and ibogaine all live here today.

Schedule II is high abuse potential with accepted medical use. Prescribable but tightly controlled, no refills. Morphine, oxycodone, fentanyl, Adderall, Ritalin.

Schedule III is moderate to lower abuse potential with accepted use. Refillable, can be called into a pharmacy. Ketamine, testosterone, buprenorphine, Tylenol with codeine.

Schedules IV and V cover lower-risk substances like Xanax, Ambien, and codeine cough syrup.

Where psychedelics are likely to land is Schedule III. Once the FDA approves one, the DEA has to reschedule it, and legal analysts across the field keep landing on Schedule III as the likeliest spot. The precedents all point there. Spravato, the esketamine nasal spray, is Schedule III. Ketamine is Schedule III. Marinol, synthetic THC, is Schedule III.

Here's the nuance most coverage gets wrong: the DEA reschedules the specific FDA-approved drug product, not the underlying substance. Cannabis is the clearest example. Marijuana itself stays Schedule I, but the approved synthetic-THC pill Marinol is Schedule III and the CBD drug Epidiolex is Schedule V. Expect the same here. If Compass's COMP360 is approved, that product gets rescheduled. Psilocybin mushrooms, grown at home or anywhere else, stay Schedule I. Same for MDMA and for any LSD product. The approved formulation moves. The substance doesn't.

And no, you won't pick it up at CVS. The closest model we have is Spravato, and that's the template to expect. Even as a Schedule III drug, Spravato is never dispensed at retail pharmacies. It moves through a closed system: a specialty pharmacy ships it to a clinic certified under a REMS program (Risk Evaluation and Mitigation Strategy, the FDA's safety framework for high-risk drugs), where the patient takes it under direct observation, is monitored, and never carries it home. Expect approved psilocybin and methylone to work the same way. The schedule matters for enforcement, taxes, and legal status. The patient experience will look like a clinic visit, not a pharmacy refill.

What rescheduling doesn't touch: because it's product-specific, nothing outside the approved drug moves. Oregon and Colorado service centers, which use non-FDA-approved psilocybin, keep operating under Schedule I federal law. Ayahuasca ceremonies, home-grown mushrooms, underground practitioners, all of it stays where it is. Rescheduling doesn't legalize recreational use, doesn't decriminalize possession outside a clinical pathway, and doesn't reach the broader plant-medicine world.
‍

The timelines

Now (spring 2026). The first three vouchers are issued. Compass is on a rolling NDA review and plans to submit by year's end. The other programs are further back.

Summer 2026. Commissioner Makary has said FDA decisions could come "later this summer." Since Compass isn't targeting its submission until late 2026, any summer decision would have to come from an application not yet public or a program moving faster than its stated timeline. Treat summer as optimistic.

Late 2026 to early 2027. This is the realistic window for the first approval of a classic psychedelic, almost certainly COMP360. Compass has said it aims to be launch-ready by the end of 2026. With rescheduling review allowed to start at Phase 3 completion, some of the usual post-approval lag can be pre-consumed.

2027 and 2028. The rest of the pipeline catches up. The LSD programs report more Phase 3 data through 2026. Methylone, MDMA, and the ibogaine-derivative work are further out. For ibogaine itself, the cardiac-safety problem still has to be solved before approval-track data exists, which points to 2028 at the earliest.

What access will actually look like

The federal model is pharmaceutical, medicalized, and clinic-based. Approved psychedelics will almost certainly run through a closed distribution system modeled on Spravato: specialty pharmacy to certified clinic, taken under direct observation, monitored, never sent home. Even at Schedule III, these products won't be on retail shelves. You'll go to a certified clinic to receive treatment.

Expected rollout order, based on where the programs actually stand:

1. Psilocybin (Compass COMP360) for treatment-resistant depression. Two positive Phase 3 trials. Rolling NDA plus a voucher. Submission targeted for late 2026. The frontrunner.
2. Psilocybin (Usona) for major depressive disorder. Phase 3, voucher in hand, application not yet filed, commercial path uncertain.
3. Methylone (Transcend/Otsuka TSND-201) for PTSD. Voucher in hand but only now entering Phase 3, so an approval is further out than the voucher suggests.
4. MDMA (Resilient, formerly Lykos) for PTSD. No voucher. Turned down in 2024, data under audit, resubmission timing unclear.
5. LSD programs for anxiety and depression. Multiple Phase 3 readouts moving through 2026.
6. Ibogaine and noribogaine. The noribogaine study for alcohol use disorder is the first foothold. Ibogaine itself stays on a longer horizon because of cardiac risk, though a 2024 Stanford study in veterans with traumatic brain injury showed that pairing ibogaine with magnesium substantially lowers that risk, and the magnesium protocol is becoming standard in research settings. The Texas consortium and the federal match are pushing this work forward, but approval-track data is likely years out.

The next big open question is insurance. If the full treatment, meaning preparation, dosing, and integration, runs $8,000 to $15,000 and isn't reimbursed, access skews hard toward people who can pay out of pocket.

Who gets access first

Veterans. The order puts veterans at the front through VA trial participation, the data-sharing agreements, and the ibogaine provisions. Veteran advocacy drove this whole moment. Veterans with serious mental illness, PTSD, or TBI have the cleanest path.

Clinical-trial participants. ClinicalTrials.gov is the place to look. VA and industry trials are running across the country. Trial participation is still the fastest, most supported route.

Patients with serious conditions who've exhausted standard treatment. As the FDA and DEA build the Right to Try pathway, these patients may become eligible for investigational access. Timing depends on how the regulators implement it.

The general public. Approval, rescheduling, REMS setup, clinician training, and clinic buildout all stack up to 2027 for the earliest realistic clinic access, and 2028 before it's broad enough to matter at scale.
‍

What the order doesn't cover

Religious use. Ayahuasca churches, peyote practitioners outside the Native American Church, and other spiritual communities stay under existing DEA posture. The order is silent on them.

State programs. Oregon's and Colorado's service centers run under state authority. The order neither expands nor protects them. They face the same federal posture they did before.

Underground practitioners. The order assumes FDA-approved products in clinical settings. Community and underground practice gain nothing here.

Therapy standards. The order speeds up drug review but sets no standards for therapist training, preparation, monitoring, or integration. The 2024 MDMA rejection was largely about exactly these container issues. Those questions are still open. It's worth noting that the American Psychiatric Association, responding to the order, called for an evidence-driven approach and cautioned that the science doesn't yet support broad rollout.
‍

A note on the rollout

The clinical work around a psychedelic session, the screening, preparation, support during the session, and integration afterward, does as much to shape the outcome as the medicine. As approvals arrive and access widens, the field will need real screening and integration infrastructure to match the scale. The guiding principles are the same ones that apply to any new medicine. Do no harm. Improve efficacy. Minimize risk.

One practical constraint worth naming: a psilocybin or methylone session runs six to eight hours, against the roughly two hours of monitoring Spravato requires. That has real implications for clinic space and for the workforce. The number of trained providers is small relative to the demand approval will create. Expect the training pipeline to be a near-term bottleneck even once the drugs are available.
‍

If you're looking for this work

1. If you're a veteran, ask your VA clinic about current psychedelic trial participation. VA facilities across several states are actively running studies.
2. If you meet diagnostic criteria but aren't a veteran, search ClinicalTrials.gov for Compass, Usona, Transcend, and Resilient studies. Trial enrollment is the fastest supported path. Know that commercial trials often exclude people with active suicidality, recent substance use, or certain other conditions, so eligibility isn't universal.
3. If you want psychedelic-adjacent treatment now, ketamine is the only FDA-legal option widely available. Spravato is approved for treatment-resistant depression and runs through the same certified-clinic model the psychedelics will use. Off-label IV and intramuscular ketamine clinics operate nationwide. Neither is a classic psychedelic, but both are the near-term reality.
4. If you're seriously ill and have exhausted standard treatment, watch for the Right to Try pathway the order directs the FDA and DEA to build. Timing depends on implementation. Until then, trial enrollment is the most reliable route.
5. If you live in Oregon or Colorado, state psilocybin service centers are already operating. For people with treatment-resistant conditions who can travel, these are the single fastest legal path to supervised psilocybin in the country right now. They run under state authority, not federal, so eligibility and cost work differently than approved access will.
6. Whatever the pathway, work with a clinician experienced in psychedelic-assisted therapy. Ask about preparation, session support, and integration before you start.
7. Don't wait for approval to begin. Even on compressed timelines, most people won't have clinic access for eighteen to thirty-six months. The preparatory work can start now.
   ‍

Bottom line

The order speeds up FDA review of psychedelic medicines, directs the FDA and DEA to build access through the existing Right to Try Act, and puts veterans first. The first three vouchers went to two psilocybin programs and one MDMA-like compound, with Compass's psilocybin for treatment-resistant depression the clear frontrunner. The first approval is realistic in late 2026 or early 2027, and most people will see access in 2027 to 2028. Approved psychedelics will almost certainly be rescheduled to Schedule III and delivered through a closed, clinic-based system, not retail pharmacies. State programs, religious practice, and underground work continue under their existing rules.
‍

If you're looking for this work, the most useful things you can do now are understand your pathway, find a qualified clinician, and watch the implementation details this order set in motion.
‍

Steve Elfrink is a psychedelic and somatic therapist based in Southern Oregon.

‍